, Volume 56, Issue 1, pp 49–57 | Cite as

A Practical Guide to Prescribing Hormone Replacement Therapy

Disease Management


Over the past 20 years there has been increasing interest in the menopause and hormone replacement therapy (HRT). More recently, postmenopausal HRT has been seen as a specific treatment for symptoms in the short term and preventative therapy in the long term. Women must be counselled regarding the risks and benefits of HRT according to the best available evidence. The patient should also be actively involved in the decision regarding HRT therapy, which should then improve patient compliance.

Generally, an appropriate regimen of HRT can be formulated for the majority of patients. Progestogen should be added to therapy in women with an intact uterus in a cyclical or continuous regimen. The management of common estrogenic and progestogenic adverse effects is important in improving compliance. At present, new drugs are being developed for the management of the menopause (selective estrogen receptor modulators and phytoestrogens). Obviously, further research will be necessary to determine whether these drugs have advantages over regular HRT.

By offering postmenopausal women HRT an attempt is made to optimise their physical and psychological well-being. However, HRT is not without adverse effects, the most worrying of which is the possible increase in breast cancer risk with long term use. However, with patient education efforts, treatment regimens acceptable to both patient and practitioner can be initiated; in this regard, the aim of the practitioner should be to help the menopausal woman make the decision which is the most appropriate for her.


Adis International Limited Breast Cancer Risk Hormone Replacement Therapy Obstet Gynecol Tibolone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McKinlay JB, McKinlay SM, Brambilla DJ. Health status and utilization behaviour associated with menopause. Am J Epidemiol 1987; 125(1): 110–21PubMedGoogle Scholar
  2. 2.
    O’Donohue J, Williams R. Hormone replacement therapy in women with liver disease. Br J Obstet Gynaecol 1997; 104: 1–3PubMedGoogle Scholar
  3. 3.
    Glueck CJ, McMahon RE, Bouquot JE, et al. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med 1997; 130: 540–3PubMedCrossRefGoogle Scholar
  4. 4.
    Vandenbrouke JP, Heimerhorst FM, Bloemenkamp KWN, et al. Third generation oral contraceptives and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997; 177: 887–91CrossRefGoogle Scholar
  5. 5.
    Glueck CJ, Lang J, Hamer T, et al. Severe hypertriglyceridaemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123(1): 59–64PubMedGoogle Scholar
  6. 6.
    Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996 Oct 12; 348(9033): 977–80PubMedCrossRefGoogle Scholar
  7. 7.
    Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996 Oct 12; 348(9033): 981–3PubMedCrossRefGoogle Scholar
  8. 8.
    Grodstein F, Stampfer MJ, Goldhaber SZ. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996 Oct 12; 348(9033): 983–7PubMedCrossRefGoogle Scholar
  9. 9.
    Creasman WT. Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol 1991; 77(2): 308–12PubMedCrossRefGoogle Scholar
  10. 10.
    Stoll BA, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet 1988; I(8597): 1278–9CrossRefGoogle Scholar
  11. 11.
    Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165(3): 372–5PubMedCrossRefGoogle Scholar
  12. 12.
    Bagdade JD, Wolter J, Subbaiah PV et al. Effects of tamoxifen treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab 1990; 70: 1132–5PubMedCrossRefGoogle Scholar
  13. 13.
    Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6PubMedCrossRefGoogle Scholar
  14. 14.
    Pfeffer RI, Kurosaki TT, Charlton SK. Estrogen use and blood pressure in later life. Am J Epidemiol 1979; 110(4): 469–78PubMedGoogle Scholar
  15. 15.
    Hassager C, Christiansen C. Blood pressure during oestrogen/progestogen substitution therapy in healthy post-menopausal women. Maturitas 1988; 9(4): 315–23PubMedCrossRefGoogle Scholar
  16. 16.
    Lobo R, March CM, Goebelsmann U, et al. Subdermal estradiol pellets following hysterectomy and oophorectomy: effect upon serum estrone, estradiol, luteinizing hormone, folliclestimulating hormone, corticosteroid binding globulin-binding capacity, testosterone-estradiol binding globulin capacity, lipids and hot flushes. Am J Obstet Gynecol 1980; 138: 714–9PubMedGoogle Scholar
  17. 17.
    Cardozo L, Gibb DMF, Tuck SM, et al. The effects of subcutaneous implants during the climacteric. Maturitas 1984; 5(3): 177–84PubMedCrossRefGoogle Scholar
  18. 18.
    Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987; 49(4): 397–409PubMedGoogle Scholar
  19. 19.
    Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flushes with transdermal administration of clonidine. Am J Obstet Gynecol 1987; 156: 561–5PubMedGoogle Scholar
  20. 20.
    Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone: the Menopause Study Group. Am J Obstet Gynecol1994 May; 170 (5 Pt 1): 1213–23PubMedGoogle Scholar
  21. 21.
    Varma TR. Effect of long-term therapy with estrogen and progesterone on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand 1985; 64(1): 41–6PubMedCrossRefGoogle Scholar
  22. 22.
    Strickland DM, Hammond TL. Postmenopausal estrogen replacement in a large gynecologic practice. Am J Obstet Gynecol Health 1988; 2: 33–5Google Scholar
  23. 23.
    Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate: the Menopause Study Group. Obstet Gynecol1994; 83 (5 Pt 1): 686–92PubMedGoogle Scholar
  24. 24.
    Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336(8710): 265–9PubMedCrossRefGoogle Scholar
  25. 25.
    Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166(3): 950–5PubMedGoogle Scholar
  26. 26.
    Pye JK, Mansell RE, Hughs LE. Clinical experience of drug treatments for mastalgia. Lancet 1985; II(8451): 373–7CrossRefGoogle Scholar
  27. 27.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350(9084): 1047–59CrossRefGoogle Scholar
  28. 28.
    Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24PubMedGoogle Scholar
  29. 29.
    Quigley MET, Martin PL, Burnier AM et al. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987; 156: 1516–23PubMedGoogle Scholar
  30. 30.
    Draper MW, Flowers DE, Huster Wet al. Effects of raloxifene (LY 139481) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. In: Christiansen C, Riis B, editors. Proceedings of the Fourth International Symposium on Osteoporosis and Consensus Development Conference. Aalborg, Denmark: Handelstrykkeriet Aalborg Aps, 1993: 119–21Google Scholar
  31. 31.
    Wilcox G, Wahlquist ML, Burger HG et al. Oestrogen effects of plant derived foods in postmenopausal women. BMJ 1990; 301: 905–6PubMedCrossRefGoogle Scholar

Copyright information

© Adls International Limited 1998

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyQueen’s University of Belfast, Institute of Clinical ScienceBelfastNorthern Ireland

Personalised recommendations